Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Rhea-AI Summary
Tiziana Life Sciences (Nasdaq: TLSA) has fully enrolled 48 patients in INFORM-MS, its randomized, double-blind, placebo-controlled Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
The 12-week study includes PET, MRI and biomarker assessments, followed by a six-month open-label extension. Topline data are expected in late Q3 2026 and will be presented at ACTRIMS/ECTRIMS in October 2026.
AI-generated analysis. Not financial advice.
Positive
- Full enrollment of 48 patients in Phase 2a INFORM-MS trial
- First Phase 2 placebo-controlled study of intranasal foralumab in na-SPMS
- Defined timeline with topline data expected late Q3 2026
- Comprehensive endpoints including PET, MRI, clinical and biomarker assessments
- Six-month open-label extension to assess long-term safety and sustained benefit
Negative
- No efficacy or safety results available until late Q3 2026
- Current data set limited to 48 Phase 2a patients, an early-stage sample
Market Reaction – TLSA
Following this news, TLSA has gained 5.59%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.6% during the session. Our momentum scanner has triggered 11 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.70. This price movement has added approximately $11M to the company's valuation. Trading volume is very high at 4.2x the average, suggesting strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
TLSA gained 16.67% while peers were mixed: TRDA up 5.96%, SLS up 8.4% in sector data but flagged as moving down in momentum scans, and KYTX/THRD slightly negative. Moves do not show a unified biotech rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 19 | SPMS EAP data | Positive | +4.0% | Updated expanded-access data for intranasal foralumab in na-SPMS patients. |
| Jan 20 | na-SPMS study paper | Positive | -6.0% | Peer-reviewed publication of open-label intranasal foralumab na-SPMS results. |
| Dec 17 | Alzheimer’s dosing start | Positive | -5.8% | First patient dosed in Phase 2 Alzheimer’s trial of intranasal foralumab. |
| Dec 12 | Alzheimer’s enrollment | Positive | +3.5% | Announcement that enrollment began for Phase 2 early Alzheimer’s trial. |
| Nov 25 | ALS trial program | Positive | +5.2% | ALS Phase 2 intranasal foralumab trial accepted into Healey ALS MyMatch. |
Clinical-trial news has produced mixed reactions, with 3 aligned and 2 divergent price moves.
Over the past several months, Tiziana has repeatedly reported progress for intranasal foralumab in neuroinflammatory indications. Prior clinical trial updates covered expanded-access data in non-active SPMS, peer-reviewed publication of an open-label na-SPMS study, and initiation milestones for Phase 2 programs in Alzheimer’s disease and ALS (Nov 2025–Jan 2026). Market reactions to these trial milestones have varied, sometimes positive and sometimes negative, so today’s strong move on completion of Phase 2a enrollment in na-SPMS extends an already active clinical news flow rather than starting a new trend.
Historical Comparison
Past clinical-trial headlines moved TLSA by an average of 0.18%. Today’s 16.67% jump on Phase 2a full enrollment is far larger than prior typical reactions.
Clinical-trial news shows a progression from early Phase 2 starts in Alzheimer’s and ALS to expanded na-SPMS data and now full Phase 2a enrollment completion in na-SPMS.
Market Pulse Summary
The stock is up +8.7% following this news. A strong positive reaction aligns with the completion of enrollment for the INFORM-MS Phase 2a na-SPMS trial, a clear clinical milestone. Historically, TLSA’s clinical-trial news moved the stock by an average of only 0.18%, so today’s 16.67% gain stands out. With shares still 38.08% below the $2.60 52-week high and volume at 1.68x average, traders should consider that prior trial headlines have sometimes seen subsequent reversals.
Key Terms
phase 2a medical
placebo-controlled medical
double-blind medical
multiple sclerosis medical
pet imaging medical
microglial activation medical
biomarkers medical
open label extension medical
AI-generated analysis. Not financial advice.
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026.
The trial (NCT06292923), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this novel anti-CD3 monoclonal antibody for neurodegenerative and neuroinflammatory diseases. The multicenter study has enrolled 48 patients across multiple leading U.S. sites to receive one of two doses of intranasal foralumab or placebo over a 12-week treatment period, with assessments including PET imaging for microglial activation, MRI, clinical evaluations, and biomarkers. Following the completion of the blinded phase, all participants including those who initially received placebo will have the opportunity to receive intranasal foralumab during a six-month open label extension (OLE) phase. The OLE is designed to assess long term safety and sustained benefit of foralumab in the na-SPMS patient population.
“This completion of enrollment in our Phase 2a trial represents a pivotal moment for Tiziana Life Sciences and for patients suffering from na-SPMS, a condition with limited treatment options,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “As the first placebo-controlled trial of intranasal foralumab, this study underscores our commitment to rigorously evaluating this innovative therapy’s potential to modulate the immune system and address neuroinflammation. We are grateful for the dedication of our clinical partners and look forward to sharing topline results that could pave the way for a new treatment paradigm.”
Gabriele Cerrone, Executive Chairman and Founder of Tiziana Life Sciences, added: “Reaching full enrollment in this landmark study is a testament to the strong belief in foralumab’s potential and the urgent need for effective therapies in secondary progressive MS. Intranasal delivery offers a novel, non-invasive route that targets the brain’s immune mechanisms directly. This achievement highlights the progress of our pipeline and brings us closer to delivering transformative benefits to patients.”
The Company extends its sincere gratitude to the Principal Investigator, Dr. Tanuja Chitnis, Senior Neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system along with the entire team of investigators and clinical sites for their exceptional commitment and expertise in advancing this important trial.
For more information on the trial, please visit ClinicalTrials.gov (NCT06292923).
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2],[3]
About Tiziana Life Sciences
Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Tiziana's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Tiziana's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of Tiziana only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Tiziana will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
[3] https://www.neurology.org/doi/10.1212/NXI.0000000000200543
